Ken Blount Healthcare News

This is selected healthcare news for Ken Blount, which is filed under People. There are 19 news items for this page. A press release filter page is also available for Ken Blount.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
7/5/2022 Microbiome Therapeutics Innovation Group Announces New Chairman
... health care costs, today announced the appointment of a new Chairman, Nikole Kimes, Ph.D, Founder & Chief Executive Officer of Siolta Therapeutics, Inc. Dr. Kimes replaces Ken Blount, Ph.D., Chief Scientific Officer of Rebiotix, Inc. and Vice President of Microbiome Research at Ferring Pharmaceuticals, who has served as MTIG Chair since ...
PR Newswire
7/5/2022 Microbiome Therapeutics Innovation Group Announces New Chairman
... health care costs, today announced the appointment of a new Chairman, Nikole Kimes, Ph.D, Founder & Chief Executive Officer of Siolta Therapeutics, Inc. Dr. Kimes replaces Ken Blount, Ph.D., Chief Scientific Officer of Rebiotix, Inc. and Vice President of Microbiome Research at Ferring Pharmaceuticals, who has served as MTIG Chair since ...
PR Newswire
7/5/2022 Microbiome Therapeutics Innovation Group Announces New Chairman
... health care costs, today announced the appointment of a new Chairman, Nikole Kimes, Ph.D, Founder & Chief Executive Officer of Siolta Therapeutics, Inc. Dr. Kimes replaces Ken Blount, Ph.D., Chief Scientific Officer of Rebiotix, Inc. and Vice President of Microbiome Research at Ferring Pharmaceuticals, who has served as MTIG Chair since ...
Yahoo News
6/3/2022 Investigative Treatment for C. Diff Aims to Restore Microbiome, Bile Acid
In an interview with Pharmacy Times, Ken Blount, PhD, chief scientific officer at Rebiotix, discusses the investigative treatment RBX2660 and its unique approach to treating Clostridioides difficile ( C. diff ) infection. Blount explained that the treatment works by restoring the microbiome and bile acid, which is essential to improving outcomes and ...
Pharmacy Times
4/25/2022 Bio-Me Joins Microbiome Therapeutics Innovation Group
... based technology. Bio-Me also offers services for fecal sample collection and sample preparation. "MTIG is pleased to welcome Bio-Me to our coalition", commented Ken Blount , Ph.D., Chief Scientific Officer of Rebiotix Inc., Vice President of Microbiome Research at Ferring Pharmaceuticals, and Chairman of MTIG. He continues: "MTIG continues ...
PR Newswire
2/9/2022 Arc Bio Joins Microbiome Therapeutics Innovation Group
... saving products to doctors and patients," commented CEO of Arc Bio, Dr. Todd Dickinson . "We are pleased to welcome Arc Bio to our coalition," said Ken Blount , Ph.D., Chief Scientific Officer of Rebiotix Inc., Vice President of Microbiome Research at Ferring Pharmaceuticals and Chairman of MTIG. "As our second member ...
PR Newswire
2/9/2022 Arc Bio Joins Microbiome Therapeutics Innovation Group
... saving products to doctors and patients," commented CEO of Arc Bio, Dr. Todd Dickinson . "We are pleased to welcome Arc Bio to our coalition," said Ken Blount , Ph.D., Chief Scientific Officer of Rebiotix Inc., Vice President of Microbiome Research at Ferring Pharmaceuticals and Chairman of MTIG. "As our second member ...
PR Newswire
10/6/2019 RBX2660 safe, efficacious for recurrent C. difficile prevention
... open-label study presented at IDWeek. “ C. difficile infections are a significant problem worldwide, primarily with respect to recurrence and the ongoing propagation of recurrence,” Ken Blount, PhD, chief scientific officer of Rebiotix Inc., said in a presentation. “As it is also becoming very clear, microbiota restoration is needed for ...
healio.com
10/1/2019 Microbiome Therapeutics Innovation Group Highlights Member Company Activity at IDWeek 2019
... and epidemiology of infectious diseases. "IDWeek is one of the premier conferences each year that showcases the advancements and innovations aimed at helping patients," said Ken Blount , Chief Scientific Officer of Rebiotix (a Ferring company) and MTIG Chair. "Many of the member companies for MTIG will be on hand to ...
PR Newswire
10/1/2019 Microbiome Therapeutics Innovation Group Highlights Member Company Activity at IDWeek 2019
... and epidemiology of infectious diseases. "IDWeek is one of the premier conferences each year that showcases the advancements and innovations aimed at helping patients," said Ken Blount , Chief Scientific Officer of Rebiotix (a Ferring company) and MTIG Chair. "Many of the member companies for MTIG will be on hand to ...
BioSpace
8/21/2019 Rebiotix, Inc and Karolinska Institutet Expand Partnership to Shape the Future of Microbiome Research
ROSEVILLE, Minn.--(BUSINESS WIRE)--Aug 21, 2019-- Rebiotix Inc, a Ferring Pharmaceuticals company, announced today that their Chief Scientific Officer, Dr. Ken Blount, has been appointed to Karolinska Institutet's Joint Steering Committee (JSC) of the Centre for Translation Microbiome Research (CTMR) in Stockholm, Sweden. Dr. Blount joins two colleagues from ...
Business Wire
7/17/2019 Siolta Therapeutics Joins Microbiome Therapeutics Innovation Group
... extensive knowledge of the developing infant gut microbiome and its role in targeted human microbiome therapeutics for the prevention and treatment of inflammatory diseases," said Ken Blount , Ph.D., Chief Scientific Officer of Rebiotix, Inc. and Chairman of MTIG. "We are eager to have Siolta Therapeutics participate in our coalition to ...
PR Newswire
7/17/2019 Siolta Therapeutics Joins Microbiome Therapeutics Innovation Group
... extensive knowledge of the developing infant gut microbiome and its role in targeted human microbiome therapeutics for the prevention and treatment of inflammatory diseases," said Ken Blount , Ph.D., Chief Scientific Officer of Rebiotix, Inc. and Chairman of MTIG. "We are eager to have Siolta Therapeutics participate in our coalition to ...
Business Insider
7/16/2019 Seed Health Joins Microbiome Therapeutics Innovation Group
... unmet medical needs makes the company a valuable partner in MTIG's mission to accelerate microbiome therapeutic development as a radical new approach to medicine," said Ken Blount , Ph.D., Chief Scientific Officer of Rebiotix, Inc. and Chairman of MTIG. "Microbiome science is progressing scientifically and clinically at a rapid pace. While ...
PR Newswire
7/2/2019 Microbiome Therapeutics Innovation Group Announces New Chairman
WASHINGTON The Microbiome Therapeutics Innovation Group (MTIG) announced today the appointment of a new chairman, Ken Blount , Ph.D., Chief Scientific Officer of Rebiotix, Inc. Dr. Blount replaces Tom DesRosier, Esq. , Chief Legal Officer of Seres Therapeutics, who served as MTIG Chairman since the coalition's inception in 2018. Tom DesRosier will ...
PR Newswire
7/2/2019 Microbiome Therapeutics Innovation Group Announces New Chairman
WASHINGTON , July 2, 2019 /PRNewswire/ -- The Microbiome Therapeutics Innovation Group (MTIG) announced today the appointment of a new chairman, Ken Blount , Ph.D., Chief Scientific Officer of Rebiotix, Inc. Dr. Blount replaces Tom DesRosier, Esq. , Chief Legal Officer of Seres Therapeutics, who served as MTIG Chairman since the coalition's inception in ...
Business Insider
6/27/2019 Rebiotix Leaders to Discuss Microbiome Product Development Challenges and Regulation at Microbiome Movement – Drug Development Summit 2019
ROSEVILLE, Minn.- Rebiotix, Inc, a Ferring Pharmaceuticals company, announced today that two members of their senior leadership team, Dr. Ken Blount, Chief Scientific Officer and Dr. Edward Burd, Head of Regulatory Affairs, will engage in key panel discussions at the 2019 Microbiome Movement - Drug Development Summit . The fourth annual summit ...
Business Wire
6/26/2019 Rebiotix Leaders to Discuss Microbiome Product Development Challenges and Regulation at Microbiome Movement – Drug Development Summit 2019 | Business & Finance | heraldchronicle.com
ROSEVILLE, Minn.--(BUSINESS WIRE)--Jun 26, 2019-- Rebiotix, Inc, a Ferring Pharmaceuticals company, announced today that two members of their senior leadership team, Dr. Ken Blount, Chief Scientific Officer and Dr. Edward Burd, Head of Regulatory Affairs, will engage in key panel discussions at the 2019 Microbiome Movement - Drug Development ...
Business Wire
5/17/2019 Microbiota Restoration Takes the Podium at DDW 2019: Investigational Microbiota-Based Therapies for Recurrent C. diff Highlighted
... in San Diego, California. “There is a growing body of evidence that indicates the microbiome has great potential in fighting or reducing disease,” said Dr. Ken Blount, Chief Scientific Officer at Rebiotix. “ One of the unmet needs, especially regarding recurrent C. diff infection, is the lack of standardized formulations that ...
Business Wire